[HTML][HTML] Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

IB Yera-Alos, L Alonso-Carbonell… - BMC Pharmacology and …, 2013 - Springer
Background After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …

Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

IB Yera-Alos, L Alonso-Carbonell… - BMC …, 2013 - pubmed.ncbi.nlm.nih.gov
Background After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …

[PDF][PDF] Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

IB Yera-Alos, L Alonso-Carbonell… - 2013 - Citeseer
Background: After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …

[HTML][HTML] Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

IB Yera-Alos, L Alonso-Carbonell… - BMC Pharmacology & …, 2013 - ncbi.nlm.nih.gov
Background After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …

Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers.

IB Yera-Alos, L Alonso-Carbonell… - BMC Pharmacology …, 2013 - search.ebscohost.com
Background: After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …

[HTML][HTML] Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

IB Yera-Alos… - BMC …, 2013 - bmcpharmacoltoxicol.biomedcentral …
After several exploratory and confirmatory clinical trials, the intralesional administration of
human recombinant epidermal growth factor (hrEGF) has been approved for the treatment of …

[PDF][PDF] Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

IB Yera-Alos, L Alonso-Carbonell… - 2013 - cyberleninka.org
Background: After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …

[PDF][PDF] Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

IB Yera-Alos, L Alonso-Carbonell… - 2013 - researchgate.net
Background: After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …

Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers.

IB Yera-Alos, L Alonso-Carbonell… - BMC Pharmacology & …, 2013 - europepmc.org
Background After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …

[PDF][PDF] Active post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers

IB Yera-Alos, L Alonso-Carbonell… - 2013 - scienceopen.com
Background: After several exploratory and confirmatory clinical trials, the intralesional
administration of human recombinant epidermal growth factor (hrEGF) has been approved …